Head-To-Head Review: Lexicon Pharmaceuticals (NASDAQ:LXRX) vs. BridgeBio Pharma (NASDAQ:BBIO)

BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) and Lexicon Pharmaceuticals (NASDAQ:LXRX – Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, valuation, institutional ownership and risk.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for BridgeBio Pharma and Lexicon Pharmaceuticals, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BridgeBio Pharma 1 2 19 0 2.82
Lexicon Pharmaceuticals 1 1 3 0 2.40

BridgeBio Pharma presently has a consensus price target of $104.42, suggesting a potential upside of 37.34%. Lexicon Pharmaceuticals has a consensus price target of $5.80, suggesting a potential upside of 279.08%. Given Lexicon Pharmaceuticals’ higher probable upside, analysts plainly believe Lexicon Pharmaceuticals is more favorable than BridgeBio Pharma.

Earnings and Valuation

This table compares BridgeBio Pharma and Lexicon Pharmaceuticals”s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
BridgeBio Pharma $502.08 million 29.50 -$724.93 million ($3.04) -25.01
Lexicon Pharmaceuticals $49.80 million 13.68 -$50.34 million ($0.14) -10.93

Lexicon Pharmaceuticals has lower revenue, but higher earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Lexicon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

BridgeBio Pharma has a beta of 0.97, indicating that its stock price is 3% less volatile than the S&P 500. Comparatively, Lexicon Pharmaceuticals has a beta of 1.1, indicating that its stock price is 10% more volatile than the S&P 500.

Institutional & Insider Ownership

99.8% of BridgeBio Pharma shares are held by institutional investors. Comparatively, 74.7% of Lexicon Pharmaceuticals shares are held by institutional investors. 14.2% of BridgeBio Pharma shares are held by company insiders. Comparatively, 14.0% of Lexicon Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares BridgeBio Pharma and Lexicon Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
BridgeBio Pharma -59.84% N/A -39.81%
Lexicon Pharmaceuticals -161.80% -35.76% -24.53%

Summary

BridgeBio Pharma beats Lexicon Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

About BridgeBio Pharma

(Get Free Report)

BridgeBio Pharma is a biopharmaceutical company that discovers, develops and commercializes medicines for genetic diseases and cancers. Founded in 2015, the company advances programs through a network of research and development subsidiaries focused on specific conditions and therapeutic areas. Its products include Attruby (acoramidis), an FDA-approved treatment for adults with transthyretin amyloid cardiomyopathy. BridgeBio also develops a pipeline of investigational therapies aimed at diseases with well-understood genetic causes, including rare and inherited conditions.

About Lexicon Pharmaceuticals

(Get Free Report)

Lexicon Pharmaceuticals is a biopharmaceutical company based in The Woodlands, Texas. Founded in 1995 as Lexicon Genetics, the company uses drug discovery and development research to create medicines for serious diseases, with a focus on areas of unmet medical need. Its commercial product, Inpefa (sotagliflozin), is approved in the United States to reduce the risk of cardiovascular death and worsening heart failure in adults with heart failure. Lexicon also develops investigational medicines, including candidates studied for neuropathic pain and other conditions.

Receive News & Ratings for BridgeBio Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BridgeBio Pharma and related companies with MarketBeat.com's FREE daily email newsletter.